Prevention of Neural Tube Defects by Inositol and Vitamin B12 (PONTib) - Development Trial

神经管缺陷(NTD)是威胁生命的出生缺陷，其中脊柱裂最为人所知。它会导致下半身瘫痪，大小便失禁，脑积水(脑积水)和其他严重的健康问题。NTDS是常见的缺陷，每500-2000个怀孕中就有一个受到影响，在许多低收入和中等收入国家，NTDS的发生率更高。含有叶酸(FA)的补充剂，在怀孕前和怀孕前3个月服用，可以降低胎儿感染NTD的风险。然而，尽管服用了FA补充剂，许多妇女仍然生下了患有NTDS的婴儿。这一经验表明，30%-50%的非专利药物对FA具有抵抗力，因此需要一种不同的补充剂来有效地预防它们。我们之前在小鼠和人类身上的研究发现，肌醇(维生素B8)是一种可能的新方法，可以预防对FA无效的NTDS。其他研究表明，维生素B12可能是一种有效的补充。在肌醇或B12补充剂实际应用之前，有必要在临床试验中确认它们的有效性。本研究建议在神经营养不良发生率较高的中国进行肌醇的试点临床试验。这项相对较小的研究将为大规模的、统计上可靠的临床试验铺平道路，该试验将告诉我们是否应该在临床实践中使用肌醇、维生素B12或两者都使用。中国是开展这项工作的理想地点，因为它拥有一流的基础设施，可以找到以前患有NTD的怀孕妇女，而且人口非常多，能够招募到足够的女性受试者。这项研究的参与者将是以前有过NTD影响的怀孕并希望再次怀孕的妇女。那些同意参与的人将被随机分配到肌醇、B12、肌醇+B12或两者都不服用。根据对患NTDS高危妇女的标准护理，所有女性受试者每天将接受5毫克FA。补充剂将从受孕前开始，一直持续到怀孕12周。这项工作将由伦敦大学学院的科学家--包括NTDS和临床试验方面的专家--与北京北京大学的科学家合作完成。中国研究人员有在当地人群中进行怀孕期间研究的多年经验，例如，近年来招募了超过10万名妇女参与怀孕期间的营养研究。这项试点研究将测试是否有强大和可靠的程序来识别、招募、随机和跟踪女性受试者的怀孕。然后，我们计划进行大规模试验，阳性结果将表明对于计划怀孕的妇女，肌醇和/或维生素B12应该与FA一起作为联合补充剂服用。肌醇或B12的使用可能会在中国身上迅速实施，因为女性在计划怀孕时已经获得了免费的FA片剂。含有肌醇/B12和FA的复合片可以以较低的额外成本提供。此后，其他国家可能会推出类似的联合补充剂，以改善NTD的预防。这不仅将使个人和家庭受益，避免受到NTD影响的怀孕，而且还将使医疗保健系统在经济上受益：一个脊柱裂患者一生的医疗和社会护理费用超过50万美元。当FA的预防作用在1991年被发现时，这是基于一项与我们建议的非常相似的临床试验。FA的使用已经推广到世界上大多数国家，我们预计我们目前提出的关于全球儿童未来健康的研究也会产生类似的有益效果。

Neural tube defects (NTDs) are life-threatening birth defects, of which spina bifida is best known. It causes paralysis of the lower body, incontinence of urine and faeces, hydrocephalus ('water on the brain') and other serious health problems. NTDs are common defects, affecting 1 in every 500-2000 pregnancies and with higher frequencies in many low and middle income countries. Supplements containing folic acid (FA), when taken before conception and for the first 3 months of pregnancy, can reduce the risk of a fetus being affected by NTD. However, many women still have babies with NTDs despite taking FA supplements. This experience has shown that 30-50% of NTDs are 'FA-resistant', and for this reason a different supplement is needed to prevent them effectively. Our previous research in mice and humans identified inositol (vitamin B8) as a possible new way to prevent NTDs that do not respond to FA. Other research suggests that vitamin B12 may be an effective additional supplement. Before either inositol or B12 supplementation can be implemented in practice, it is essential to confirm their effectiveness in a clinical trial.This research proposes a pilot clinical trial of inositol in China where there is a high rate of NTDs. This relatively small study will 'pave the way' towards a large-scale, statistically robust clinical trial that will tell us whether inositol, vitamin B12 or both should be used in clinical practice. China is an ideal location for the work as it has an excellent infrastructure for locating women with previous NTD-affected pregnancies, and a very large population to enable sufficient women subjects to be recruited. The study participants will be women with a previous NTD-affected pregnancy who wish to become pregnant again. Those who consent to participate will be randomly assigned to take either inositol, B12, inositol + B12, or neither. In line with the standard care for women at high risk of NTDs, all women subjects will receive 5 mg FA daily. Supplementation will begin before conception and continue until the 12th week of pregnancy. The work will be a collaboration between scientists at University College London - including experts in NTDs and clinical trials - and scientists at Peking University in Beijing. The Chinese investigators have many years' experience of conducting studies during pregnancy in their local populations, for example having recruited over 100,000 women for a study of nutrients in pregnancy in recent years.This pilot study will test whether robust and reliable processes are in place to identify, recruit, randomise and follow up the pregnancies of the women subjects. Then, we plan to progress on to the large-scale trial, where a positive outcome would indicate that inositol and/or vitamin B12 should be taken together with FA in a combined supplement for women planning a pregnancy. The use of inositol or B12 could be rapidly implemented in China, as women already receive free FA tablets when planning a pregnancy. A combined tablet containing inositol/B12 and FA could be provided at a low additional cost. Thereafter, other countries are likely to introduce similar combined supplements to improve NTD prevention. This will not only benefit individuals and families by avoiding the impact of an NTD-affected pregnancy, but will also benefit health care systems economically: the life-time medical and social care costs of a person with spina bifida are more than $0.5M. When the preventive effect of FA was discovered in 1991, this was based on a very similar clinical trial to the one we propose. FA usage has spread to most countries in the world, and we anticipate a similar beneficial effect of our currently proposed research on the future health of children worldwide.